Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03024177
Recruitment Status : Withdrawn (Study is withdrawn due to company decision)
First Posted : January 18, 2017
Last Update Posted : May 7, 2018
Information provided by (Responsible Party):

Brief Summary:
This is a randomized, double-blind, placebo-controlled study of vapendavir treatment of laboratory-confirmed and symptomatic HRV infection of the upper respiratory tract in allogeneic and autologous stem cell transplant subjects. The aim of this study is to evaluate the effect of vapendavir on laboratory-confirmed HRV upper-respiratory tract infection in HSCT patients, as measured by viral load changes, worsening of upper respiratory tract infection (URTI) to lower respiratory tract infection (LRTI), duration of clinical symptoms, the occurrence of supplemental oxygen use, duration of viral shedding, hospital admission and duration of hospitalization, incidence of secondary bacterial infection, and mortality rates. Additionally, the safety and tolerability of vapendavir, and the vapendavir plasma levels achieved in the HSCT population, and the profile of viral resistance development will also be assessed.

Condition or disease Intervention/treatment Phase
Rhinovirus Upper Respiratory Tract Infection Drug: Vapendavir Drug: Placebo Oral Tablet Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
Actual Primary Completion Date : April 2017

Arm Intervention/treatment
Experimental: Vapendavir 528 mg Drug: Vapendavir
Vapendavir Tablets, 264 mg
Other Name: BTA798

Placebo Comparator: Placebo Drug: Placebo Oral Tablet
Vapendavir 264 mg matching tablets

Primary Outcome Measures :
  1. Efficacy: Time-weighted average change from baseline to end of treatment visit in HRV viral load (HRV-RNA log10 copies/mL) [ Time Frame: Study Day 1 to end of treatment (Study Day 14) ]
  2. Safety: Proportion of treatment-emergent adverse events [ Time Frame: Study Day 1 - 90 ]
  3. Safety: Proportion of treatment-related serious adverse events [ Time Frame: Study Day 1 - 90 ]
  4. Safety: Incidence of treatment-emergent Grade 3 or greater clinical laboratory abnormalities [ Time Frame: Study Day 1 - 90 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Allogeneic or autologous HSC transplant within last 6 months using any conditioning regimen, or HSC transplant subjects with current chronic graft vs host disease requiring systemic treatment at any time point post-transplant;
  2. Documented HRV in the upper respiratory tract (e.g., nasal swab, nasopharyngeal swab, nasal wash) as determined by local testing;
  3. Subject presents to clinic reporting symptoms of a cold with the presence of at least 2 symptoms associated with HRV infection and with an onset such that they can be randomized and dosed preferably within 72 hours but up to a 5 day window (120 hours) interval from symptom onset to study treatment initiation;
  4. Capable of giving written informed consent that includes compliance with the requirements and restrictions listed in the consent form. Informed consent and subject assent for subjects below the legal age of consent will be documented by means of a written, signed, and dated ICF and assent document. For subjects below the legal age of consent, the parent/legal guardian will provide informed consent and subjects below the legal age of consent will provide assent to participate in the study, in compliance with local regulations;
  5. Subject is able to understand and comply with the protocol requirements;
  6. Ability to maintain adequate oral intake of medication;
  7. Female subjects who are not postmenopausal for at least 2 years or surgically sterile with complete hysterectomy or bilateral oophorectomy and male subjects, who are not surgically sterile via vasectomy, must agree to use a double barrier method of birth control, such as, a condom plus spermicidal agent (foam/gel/film/cream/suppository) from the time of randomization until 30 days after completion of study drug dosing. Male subjects cannot donate sperm during the study starting at day 1 and for 90 days after completion of study drug dosing;
  8. Female subjects must not be breastfeeding or pregnant.

Exclusion Criteria:

  1. Positive test result within 5 days prior to Study Day 1 inclusive for any of the following viral respiratory pathogen that are not HRV: respiratory syncytial virus, influenza, parainfluenza, adenovirus, or human metapneumovirus;
  2. Clinically significant bacterial, fungal, or viral lower respiratory tract infection within 2 weeks prior to Study Day 1 (subject cannot have lower respiratory tract infection at Study Day 1) inclusive that has not been adequately treated, as determined by the investigator;
  3. Clinically significant systemic bacteremia or fungemia within 7 days prior to Study Day 1 that has not been adequately treated, as determined by the investigator and the Medical Monitor;
  4. Subjects receiving high dose systemic steroids defined as >2mg/kg per day or prednisone or prednisone equivalent currently or within the 7 days prior to Study Day 1;
  5. Subjects with diagnosis of a lower respiratory infection at Study Day 1, subjects with O2 saturation of less than 92% in the absence of supplemental oxygen, or those requiring invasive mechanical ventilation or non-invasive mechanical ventilation with BIPAP or CPAP at the time of randomization, and/or a history or current evidence of chronic obstructive airways disease, emphysema, cystic fibrosis or current, uncontrolled or severe asthma;
  6. Moderate to severe hepatic veno-occlusive disease (VOD), now known as moderate to severe sinusoidal obstructive syndrome (SOS), defined as meeting Baltimore Criteria for moderate or severe VOD disease;
  7. At the time of randomization, currently in hospice, or at overt risk of death, in the judgment of the investigator. If relapsed with hematologic malignancy, subject may be enrolled if status not futile and subject expected at the time of randomization to survive to complete the study;
  8. Subjects with absolute lymphocyte count of >2000 cells/mm3 within 5 days of randomization (Study Day 1);
  9. Subjects with other known clinical significant laboratory abnormalities from local lab testing performed within 30 days prior to Study Day 1 will be considered for inclusion, if in the opinion of the investigator or Medical Monitor the abnormalities will not significantly jeopardize the safety of the subject or are related to the underlying study disease and/or transplant and the abnormalities will not impair the validity of the study;
  10. Known history of estimated creatinine clearance < 50 mL/min (as calculated via the Cockcroft-Gault method);
  11. Known history of HIV/AIDS. Known history of active HBV or HCV infection that has not resolved with treatment;
  12. Current abuse of alcohol or any use of illicit drugs;
  13. Received an investigational drug or investigational vaccine within 14 calendar days or 5 half-lives (whichever is longer) which does have US market approval for a related indication or different dosing regimen, or use of an investigational medical device within 14 calendar days prior to Study Day 1, or has received vapendavir at any previous time;
  14. Subjects unable to tolerate bilateral nasopharyngeal sampling required for this study, as determined by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03024177

Sponsors and Collaborators
Layout table for investigator information
Study Director: Anna Novotney-Barry Aviragen Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Vaxart Identifier: NCT03024177    
Other Study ID Numbers: BTA798-204
First Posted: January 18, 2017    Key Record Dates
Last Update Posted: May 7, 2018
Last Verified: May 2018
Keywords provided by Vaxart:
Human rhinovirus
Hematopoietic Stem Cell Transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases